Long-Term Survival Data in EGFR-Mutated NSCLC: Applying New Evidence Across the Treatment Continuum
Dr. Roy Herbst from Dartmouth Cancer Center and Dr. Samuel Kareff from Lynn Cancer Institute discuss how emerging long-term survival data are reshaping treatment decisions across the continuum of EGFR-mutated non-small cell lung cancer (NSCLC), from the adjuvant setting through metastatic disease management. Two clinical scenarios are discussed. The first presents a patient with resected early-stage EGFR exon 19 deletion NSCLC who received immunotherapy before molecular results returned, illustrating the pitfalls of acting on PD-L1 status alone and the importance of completing next-generation sequencing before initiating systemic therapy. The second presents a patient with metastatic EGFR-mutated NSCLC and central nervous system metastases, exploring frontline combination therapy selection, local consolidative therapy considerations, post-progression biopsy strategy, and resistance mechanisms including small cell transformation and MET amplification. The 8-year ADAURA overall survival data, adjuvant osimertinib treatment adherence strategies, neoadjuvant approaches, and future directions including vaccines and leptomeningeal disease management are discussed throughout.
Advertisement
Long-Term Survival Data in EGFR-Mutated NSCLC: Applying New Evidence Across the Treatment Continuum
Dr. Roy Herbst introduces the program and presents clinical scenario 1: a 61-year-old woman with a 4-week history of dry cough, CT-confirmed 3.2 cm spiculated right lower lobe nodule, no mediastinal lymphadenopathy, SUVmax 6.8 on PET/CT, and negative brain MRI. She undergoes video-assisted thoracoscopic surgery right lower lobectomy with mediastinal lymph node dissection, yielding a 3.4 cm invasive adenocarcinoma, R0 margins, pN0, staged IIA (T2bN0M0) based on visceral pleural invasion.
Dr. Herbst, reflecting on nearly 30 years of EGFR inhibitor research, asks Dr. Kareff how he applies the ADAURA paradigm in practice. Dr. Kareff frames the conversation around the optimism that comes with identifying an actionable mutation: for patients with resected stage IB through IIIA EGFR-mutated NSCLC, he opens the adjuvant osimertinib discussion by communicating that the mutation qualifies them for targeted therapy shown to reduce recurrence risk and improve survival.
Dr. Herbst asks Dr. Kareff about the real clinical challenge of managing osimertinib toxicity across a 3-year adjuvant course, noting a fundamental difference from the metastatic setting where patients are symptomatic at baseline and often feel dramatically better when targeted therapy starts.
Dr. Herbst turns to the 8-year ADAURA overall survival data presented at the World Lung Conference, noting the trial's original primary endpoint was DFS, with OS first reported at ASCO approximately 3 years prior and now updated with 8 years of follow-up.
Dr. Kareff presents clinical scenario 2: a 68-year-old man, former light smoker (10 pack-years, quit 20 years prior), with a 2-month history of headaches and word-finding difficulty.
Dr. Herbst identifies post-progression management as the central ongoing challenge in EGFR-mutated NSCLC: even with highly effective first-line targeted therapy, median duration of response in the metastatic setting is approximately 22 to 24 months, and the disease invariably acquires resistance.
